RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. Nakagawa K, Garon EB, Seto T, Nishio M, et al. J Thorac Oncol 2025;20:487-499.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nakagawa K, Garon EB, Seto T, Nishio M, et al. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol 2025;20:487-499.
PMID: 39622410